OncoMatch/Clinical Trials/NCT06954831
Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
Is NCT06954831 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for anatomic stage i breast cancer ajcc v8.
This clinical trial tests how well ultra-hypofractionated (UF) whole breast irradiation (WBI) with lumpectomy cavity boost (CB) works in treating patients with stage I-III breast cancer. Breast conservation therapy (BCT) is the recommended treatment for patients with early stage breast cancer. BCT involves a lumpectomy followed by breast radiation. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Traditionally, WBI has been given once daily over 5-6 weeks and then those at high-risk for recurrence receive additional radiation (boost) to the lumpectomy cavity daily over 4-8 days. This has now been replaced by moderate hypofractionated radiation. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Although moderate hypofractionated radiation therapy reduces the length of treatment from 6-7 weeks to 3-4 weeks, the length of treatment still remains a barrier for many patients. UF-WBI with CB delivers radiation to the whole breast and the surgical cavity at the same time over 5 daily treatments. Giving UF-WBI with CB may prevent recurrence and prolong survival as well as improve the quality of life in patients with stage I-III breast cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Required: Stage I, II, III
Excluded: Stage IV
Demographics
Prior therapy
Must have received: breast conserving surgery
Patients must have undergone breast conserving surgery. Re-excision for negative margins is allowed
Must have received: surgical staging of the axilla
Patients must have undergone surgical staging of the axilla (sentinel lymph node biopsy or axillary lymph node dissection)
Cannot have received: radiation therapy
Prior radiation to the region of the involved breast that in the opinion of the investigator would preclude breast irradiation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope at Arcadia · Arcadia, California
- City of Hope Medical Center · Duarte, California
- City of Hope at Irvine Lennar · Irvine, California
- City of Hope Antelope Valley · Lancaster, California
- City of Hope South Pasadena · South Pasadena, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06954831 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage I or II or III is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages